Aadi Bioscience
NASDAQ: WHWKMorristown, US · Delaware corporation · 6 known investors
Find your way into Aadi Bioscience
119 people in our graph share verified history with the Aadi Bioscience team — schools, employers, funds. One of them is your warm intro.
Tom Danilekunlockedknows Dave Lennon · together at Columbia University (overlapped)
×4knows the team · via Joan & Sanford I. Weill Medical College of Cornell University
×7knows the team · via Columbia University
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
Founders & leadership
SG
Scott GiacobelloinChief Financial Officer2021–2025
BB
Bryan BallExecutive
DL
Dave LennoninPresident and CEO2023–2025Dave Lennon is an executive officer and director at Aadi Bioscience, a biotechnology company developing mTOR-targeted therapies using albumin-bound nanoparticle technology and genomic profiling.
DD
David DornanExecutive
JM
James MurphyExecutive
SP
Stephen PakolaExecutive
KG
Kevin G. PetersExecutive
MD
Margaret DuganChief Medical Officer
ND
Neil DesaiNamed on SEC filing
JG
Joseph GardnerNamed on SEC filing
Board
BZ
Baiteng ZhaoBoard director
CC
Caley CasteleinBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$451.8M disclosed across 5 of 6 rounds · 1900–2025
▶$100MraisedMar 2025 · 17 investors · BiotechnologyRule 506(b)
▶$100MraisedMar 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Baiteng ZhaoDirector
- Scott GiacobelloExecutive Officer
- Caley CasteleinDirector
- Richard MarounDirector
- Bryan BallExecutive Officer
- Behzad AghazadehDirector
- Emma ReeveDirector
- Dave LennonExecutive Officer, Director
- David DornanExecutive Officer
- Mohammad HirmandDirector
- Karin HehenbergerDirector
- Neil DesaiDirector
- Anupam DalalDirector
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $4.3M
- Placement agents
- Jefferies LLC
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$72.5MraisedOct 2022 · 13 investors · BiotechnologyRule 506(b)
▶$72.5MraisedOct 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karin HehenbergerDirector
- Brendan DelaneyExecutive Officer
- Scott GiacobelloExecutive Officer
- Caley CasteleinDirector
- Richard MarounDirector
- Loretta ItriExecutive Officer
- Neil DesaiExecutive Officer, Director
- Anupam DalalDirector
- Emma ReeveDirector
- Behzad AghazadehDirector
- Offering amount
- $72.5M
- Amount sold
- $72.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$155MraisedSep 2021 · 31 investors · BiotechnologyRule 506(b)
▶$155MraisedSep 2021 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Caley CasteleinDirector
- Neil DesaiExecutive Officer, Director
- Anupam DalalDirector
- Emma ReeveDirector
- Richard MarounDirector
- Lance ThibaultExecutive Officer
- Karin HenebergerDirector
- Offering amount
- $155M
- Amount sold
- $155M
- Finders' fees
- $9.3M
- Placement agents
- Cowen and Company LLC, Jefferies LLC, Piper Sandler & Co.
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$82.5MraisedSep 2021 · 15 investors · BiotechnologyRule 506(b)
▶$82.5MraisedSep 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anupam DalalDirector
- Neil DesaiExecutive Officer, Director
- Karin HenebergerDirector
- Richard MarounDirector
- Emma ReeveDirector
- Caley CasteleinDirector
- Lance ThibaultExecutive Officer
- Offering amount
- $82.5M
- Amount sold
- $82.5M
- Sales commissions
- $2M
- Placement agents
- Perella Weinberg Partners LP, Piper Sandler & Co.
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$41.8MraisedMar 2017 · 264 investors · BiotechnologyRule 506(b)
▶$41.8MraisedMar 2017 · 264 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Muneer SatterDirector
- Steven PrelackDirector
- Anupam DalalDirector
- Joseph GardnerExecutive Officer, Director
- James MurphyExecutive Officer
- Stephen PakolaExecutive Officer
- Pravin DugelDirector
- Chau KhuongDirector
- Kevin G. PetersExecutive Officer
- Paul M. WeissDirector
- Caley CasteleinDirector
- Offering amount
- $41.8M
- Amount sold
- $41.8M
- Sales commissions
- $4.2M
- Placement agents
- Katalyst Securities LLC, National Securities Corporation, Raymond James & Associates, Inc.
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$135.2Mvaluation at IPOJun 2017 · $5.00/share · S-1/A
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 1
by search overlap
Companies competing with Aadi Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aadi Bioscience do?
- Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.
- Who are Aadi Bioscience's investors?
- Aadi Bioscience's investors include 3B Future Health Fund, Ally Bridge Group, Decheng Capital, Vivo Capital, Avoro Ventures, OrbiMed.
- How much funding has Aadi Bioscience raised?
- Aadi Bioscience has disclosed $451.8M raised across 5 of its 6 known rounds.
- Where is Aadi Bioscience headquartered?
- Aadi Bioscience is headquartered in Morristown, US.